Claims for Patent: 9,227,031

Summary for Patent: 9,227,031

Title:	Nasal delivery device
Abstract:	A drinking actuated device for delivering a substance to the nasal cavity of a subject, comprising: a container for containing the substance; a nosepiece extending from the device for placement in proximity to the nose of a subject, with the nosepiece in fluid communication with the container; a valve mechanically connectable to the container, characterized by an active configuration and an inactive configuration; and a trigger mechanism adapted to reversibly reconfigure the valve from the active configuration to the inactive configuration. The mouthpiece is fluidly connectable to by means of a tubule to a fluid reservoir containing a fluid. Drawing liquid from the reservoir into the mouth via the mouthpiece reconfigures the valve from the inactive configuration to the active configuration for a predetermined period of time in response to the pressure gradient generated by the suction applied by the subject to the tubule.
Inventor(s):	Shahaf; Daniel (M.P. Emek Ha-Yarden, IL), Hadash; Joseph (Lapid, IL)
Assignee:	SIPNOSE LTD. (Yokne\'am Ilit, IL)
Application Number:	13/783,629
Patent Claims:	1. A drinking-actuated device configured for delivering a substance to a nasal cavity of a subject, said device comprising: a. a container for containing said substance; b. a nosepiece extending from said device for placement in proximity to a nose of said subject, said nosepiece being in fluid communication with said container; c. a valve mechanically connectable to said container, characterized by at least two configurations: (i) an active configuration in which said valve enables delivery of predetermined amount of said substance from said container to said nasal cavity via said nosepiece; and, (ii) an inactive configuration; d. a mouthpiece extending from said device for placement in a mouth of said subject; and, e. a trigger mechanism configured to reconfigure said valve from said active configuration to said inactive configuration, and vice versa; wherein said mouthpiece is fluidly connectable by means of a tubule to a fluid reservoir containing a fluid, said fluid reservoir is configured to supply said fluid to said mouth of said subject via said mouthpiece; further wherein said trigger mechanism is configured to reconfigure said valve from said inactive configuration to said active configuration for a predetermined period of time in response to a pressure gradient generated by suction applied by said subject to said tubule for drinking said fluid through said tubule. 2. The drinking-actuated device according to claim 1, wherein said trigger mechanism is configured to reconfigure said valve from said active configuration to said inactive configuration when said pressure gradient is absent. 3. The drinking-actuated device according to claim 1, wherein said trigger mechanism comprises a controlling member configured to move reciprocally in response to said pressure gradient; said controlling member is characterized by having at least two configurations: (i) a closed configuration in which said fluid is not provided to said subject via said tubule and said valve is in said inactive configuration; and, (ii) an opened configuration in which said subject drinks said fluid through said tubule and said valve is in said active configuration; further wherein in said closed configuration, said controlling member is configured to block the passage of said fluid from said fluid reservoir to said mouthpiece. 4. The drinking-actuated device according to claim 3, wherein said trigger mechanism further comprises a flexible membrane, said flexible membrane is configured to reconfigure its shape in response to said pressure gradient caused by said suction applied by said subject to said tubule, such that said controlling member is reconfigured from said closed configuration to said opened configuration, and vice versa. 5. The drinking-actuated device according to claim 4, wherein at least one of the following is being held true (a) said controlling member is characterized by at least three portions: a first end positioned at least partially within said tubule; a middle portion mechanically connected with said membrane; and, a second end in communication with said valve; (b) said controlling member comprises a first aperture fluidly communicating said flexible membrane and said mouthpiece, said first aperture is configured to transfer said pressure gradient from said tubule to said flexible membrane, so as to reconfigure said flexible membrane such that said controlling member is reconfigured from said closed configuration to said opened configuration; (c) said controlling member comprises a second aperture configured to facilitate passage of said fluid through said controlling member when said controlling member is in said opened configuration, said passage of said fluid within said second aperture is configured to preserve said controlling member in said opened configuration while said fluid passes through said controlling member; and any combination thereof. 6. The drinking-actuated device according to claim 5, wherein at least one of the following is being held true (a) said first end of said controlling member is substantially perpendicular to said tubule and substantially vertically movable within said tubule; (b) in the reconfiguration of said controlling member from said closed configuration to said opened configuration, said first end is configured to move within and with respect to said tubule; and any combination thereof. 7. The drinking-actuated device according to claim 1, wherein at least one of the following is being held true (a) said valve is reconfigurable from said inactive configuration to said active configuration when said pressure gradient is above a predetermined threshold; (b) said valve comprises a spring which is at least partially tensed in said inactive configuration, and at least partially released in said active configuration; (c) said valve comprises a spring which is at least partially released in said inactive configuration, and at least partially tensed in said active configuration; (d) said drinking of said fluid by said subject is configured to cause the soft palate of said subject to be closed, so that the nasal passageways of the nose of said subject is substantially isolated from the remainder of the pulmonary system; (e) said tubule is at least partially a straw; and any combination thereof. 8. The drinking-actuated device according to claim 1, further comprising a piston configured to compress said substance within said container; wherein said valve is configured to move said piston towards said substance when said valve is configured to said active configuration. 9. The drinking-actuated device according to claim 1, wherein the operation of said trigger mechanism is synchronized with said drinking of said fluid by said subject. 10. The drinking-actuated device according to claim 1, wherein said trigger mechanism comprises a pulsation mechanism configured to reconfigure said valve from said inactive configuration to said active configuration and vice versa in sequence of pulses, each of which is characterized by a predetermined length of pulse, said valve configured to release said predetermined amount of said substance according to said sequence of pulses. 11. The drinking-actuated device according to claim 1, wherein said nosepiece is in fluid communication with said valve by means of a spray nozzle; further wherein said spray nozzle is characterized by a diameter which influences said predetermined period of time. 12. The drinking-actuated device according to claim 1, further comprising a cap configured to cover at least a portion of the components of said device for sterilization purposes; wherein said cap comprises an opening. 13. The drinking-actuated device according to claim 1, wherein said container is configured to be connected to an external container, said external container is configured to fill said container with said substance; wherein said external container configured to fill said container with a predetermined dose of said substance. 14. The drinking-actuated device according to claim 1, further comprising indicating means configured to indicate the amount of said substance within said container; further wherein said indicating means is a transparent window located on a side of said container. 15. The drinking-actuated device according to claim 1, wherein at least one of the following is being held true (a) said fluid is selected from a group consisting of: water, a juice, a fluid medication, a cold fluid, a warm fluid, and any combination thereof; (b) said substance is used for the treatment of at least one selected from a group consisting of cholera, moraxella catarrhali, cocaine addiction, Haemophilus influenzae type b (Hib), meningococcus, measles, mumps, rubella, varicella, yellow fever, Respiratory syncytial virus, pneumococcus, streptococcus, typhoid, influenza, hepatitis, including hepatitis A, B, C and F, polio, human immunodeficiency virus (HIV), parainfluenza, rotavirus, cytomegalovirus (CMV), chlamydia, non-typeable haemophilus, moraxella catarrhalis, human papilloma virus, tuberculosis including Bacillus Calmette-Guerin (BCG), gonorrhoea, asthma, atherosclerosis, malaria, otitis media, E-coli, H. Pylori, salmonella, diabetes, cancer and herpes simplex, Staphylococcus aureus, Streptococcus, central nervous system (CNS) disorders, brain disorders such as: brain cancer, acute brain injury, spinal cord injury, Alzheimer's disease, Neurogenesis, Parkinson's disease, depression, Epilepsy, schizophrenia by the delivery of substances such as: Neurotrophins, brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), anti-epidermal growth factor receptor antibodies (anti EGF receptor AB), Enzymes such as Lysosomal enzyme, Neuregulin; and any combination thereof; (c) said substance may be delivered to said nasal cavity in a form selected from a group consisting of: a powder; a granule; a cachet; a capsule; a tablet; a paste; a cream; a gel; an ointment; a salve; a foam; a paste; a lotion; a cream; an oil suspension; a suspension; a solution; an emulsion; a patch; a stick; a spray, preferably a nasal spray, or a buccal spray; a mouth wash; an aerosol from a Venturi effect; a drink; and any combination thereof. 16. The drinking-actuated device according to claim 1, wherein said substance is a drug selected from a group consisting of: Anti-Angiogenesis agents, Antisense, anti-ulcer, butorphanol, Calcitonin and analogs, COX-II inhibitors, desmopressin and analogs, dihydroergotamine, Dopamine agonists and antagonists, Enkephalins and other opioid peptides, Growth hormone and analogs, growth hormone releasing hormone, Growth hormone antagonists, Immunoglobulin E (IgE) suppressors, Insulin, insulinotropin and analogs, Ketamine, Kytril, Leutenizing hormone releasing hormone and analogs, lidocaine, metoclopramide, Midazolam, Narcotic analgesics, neuraminidase inhibitors, nicotine, Non-steroid anti-inflammatory agents, Oligosaccharides, ondansetron, Parathyroid hormone and analogs, Parathyroid hormone antagonists, Prostaglandin antagonists, Prostaglandins, Recombinant soluble receptors, scopolamine, Serotonin agonists and antagonists, Sildenafil, Terbutaline, vasopressin, vaccine with or without carriers and/or adjuvant selected from a group consisting of: Prophylactics and therapeutic antigens, subunit protein, peptide and polysaccharide, polysaccharide conjugates, toxoids, genetic based vaccines, live attenuated, reassortant, inactivated, whole cells, viral and bacterial--vectors for the treatment of arthritis, Lactobacillus species: Lactobacillus acetotolerans, Lactobacillus acidifarinae, Lactobacillus acidipiscis, Lactobacillus acidophilus (Doderlein bacillus), Lactobacillus agilis, Lactobacillus algidus, Lactobacillus alimentarius, Lactobacillus amylolyticus, Lactobacillus amylophilus, Lactobacillus amylotrophicus, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus antri, Lactobacillus apodemi, Lactobacillus aviarius, Lactobacillus bifermentans, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus camelliae, Lactobacillus casei, Lactobacillus catenaformis, Lactobacillus ceti, Lactobacillus coleohominis, Lactobacillus collinoides, Lactobacillus composti, Lactobacillus concavus, Lactobacillus coryniformis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus diolivorans, Lactobacillus equi, Lactobacillus equigenerosi, Lactobacillus farraginis, Lactobacillus farciminis, Lactobacillus fermentum, Lactobacillus fornicalis, Lactobacillus fructivorans, Lactobacillus frumenti, Lactobacillus fuchuensis, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus gastricus, Lactobacillus ghanensis, Lactobacillus graminis, Lactobacillus hammesii, Lactobacillus hamsteri, Lactobacillus harbinensis, Lactobacillus hayakitensis, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus homohiochii, Lactobacillus iners, Lactobacillus ingluviei, Lactobacillus intestinalis, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kalixensis, Lactobacillus kefiranofaciens, Lactobacillus kefiri, Lactobacillus kimchii, Lactobacillus kitasatonis, Lactobacillus kunkeei, Lactobacillus leichmannii, Lactobacillus lindneri, Lactobacillus malefermentans, Lactobacillus mali, Lactobacillus manihotivorans, Lactobacillus mindensis, Lactobacillus mucosae, Lactobacillus murinus, Lactobacillus nagelii, Lactobacillus namurensis, Lactobacillus nantensis, Lactobacillus oligofermentans, Lactobacillus oris, Lactobacillus panis, Lactobacillus pantheris, Lactobacillus parabrevis, Lactobacillus parabuchneri, Lactobacillus paracollinoides, Lactobacillus parafarraginis, Lactobacillus parakefiri, Lactobacillus paralimentarius, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus perolens, Lactobacillus plantarum, Lactobacillus pontis, Lactobacillus psittaci, Lactobacillus rennini, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus rimae, Lactobacillus rogosae, Lactobacillus rossiae, Lactobacillus ruminis, Lactobacillus saerimneri, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus sanfranciscensis, Lactobacillus satsumensis, Lactobacillus secaliphilus, Lactobacillus sharpeae, Lactobacillus siliginis, Lactobacillus spicheri, Lactobacillus suebicus, Lactobacillus thailandensis, Lactobacillus ultunensis, Lactobacillus vaccinostercus, Lactobacillus vaginalis, Lactobacillus versmoldensis, Lactobacillus vini, Lactobacillus vitulinus, Lactobacillus zeae, Lactobacillus zymae, Probiotics selected from a group consisting of Lactic acid bacteria (LAB) and bifidobacteria, and any combination thereof; a therapeutic substance selected from a group consisting of: Agents for the common cold, Anti-addiction, anti-infectives, analgesics, anesthetics, anorexics, antiarthritics, anti-allergy agents, antiasthmatic agents, anticonvulsants, anti-depressants, antidiabetic agents, anti-depressants, anti-diuretics, anti-emetics, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations, antinauseants, antineoplastics, anti-obesity, antiosteoporeteic, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antagonists, bone stimulating agents, central nervous system stimulants, hormones, hypnotics, immunosuppressives, prostaglandins, proteins, peptides, polypeptides and other macromolecules, psychostimulants, rhinitis treatment, sedatives, sexual hypofunction, tranquilizers and vitamins including B12, probiotics, natural oils, natural ingredients, peptide or protein therapeutic agent such as cytokines, hormones, clotting factors, vaccines, monoclonal antibody, natural oils; Mint oils, Peppermint oil, Spearmint oil, Menthol, Olive oil, Eucalyptus oil, Amino acids, fatty acids and any combination thereof. 17. A method for delivering a substance to a nasal cavity of a subject, said method comprising steps of: a. providing a drinking-actuated device configured for delivering a substance to a nasal cavity of a subject, said device comprising: (i) a container for containing said substance; (ii) a nosepiece extending from said device for placement in proximity to a nose of said subject, said nosepiece being in fluid communication with said container; (iii) a valve mechanically connectable to said container, characterized by at least two configurations: (i) an active configuration in which said valve causes a delivery of predetermined amount of said substance from said container to said nasal cavity via said nosepiece; and (ii) an inactive configuration in which said substance is not delivered to the nose of said subject; (iv) a mouthpiece extending from said device for placement in a mouth of said subject; and, a trigger mechanism configured to reconfigure said valve from said active configuration on to said inactive configuration, and vice versa; (v) wherein said mouthpiece is fluidly connectable by means of a tubule to a fluid reservoir containing a fluid, said fluid reservoir is configured to supply said fluid to said mouth of said subject via said mouthpiece; b. placing said nosepiece in or around the nose of said subject; c. fluidly connecting said tubule to said fluid reservoir; d. placing said mouthpiece in the mouth of said subject; e. drinking said fluid through said mouthpiece, thereby reconfiguring said valve via said trigger mechanism from said inactive configuration to said active configuration for a predetermined period of time in response to a pressure gradient generated by suction applied to said tubule while said subject drinks said fluid through said tubule; f. releasing said predetermined amount of said substance from said container to said nosepiece wherein in a closed configuration, a controlling member is configured to block the passage of said fluid from said fluid reservoir to said mouthpiece. 18. The method for delivering a substance to a nasal cavity of a subject according to claim 17, further comprising at least one step selected from a group consisting of (a) reconfiguring said valve via said trigger mechanism from said active configuration to said inactive configuration when said pressure gradient is absent; (b) providing said trigger mechanism with said controlling member configured to move reciprocally within said tubule and said valve in responsive to said pressure gradient; said controlling member is characterized by having at least two configurations: (i) said closed configuration in which said fluid is not provided to said subject via said tubule and said valve is in said inactive configuration; and, (ii) an opened configuration in which said subject drinks said fluid through said tubule and said valve is in said active configuration; and any combination thereof. 19. The method for delivering a substance to a nasal cavity of a subject according to claim 17, further comprising steps of: providing said trigger mechanism with a flexible membrane; reconfiguring the shape of said flexible membrane in response to said pressure gradient; and, thereby reconfiguring said controlling member is from said closed configuration to said opened configuration, and vice versa. 20. The method for delivering a substance to a nasal cavity of a subject according to claim 19, wherein at least one of the following is being held true (a) said controlling member is characterized by at least three portions: a first end positioned at least partially within said tubule; a middle portion mechanically connected with said membrane; and, a second end in communication with said valve; (b) said method further comprising steps of providing said controlling member with a first aperture fluidly communicating between said membrane and said mouthpiece, transferring said pressure gradient from said tubule to said flexible membrane, thereby reconfiguring said controlling member from said opened configuration to said closed configuration; (c) said method further comprising steps of providing said controlling member with a second aperture configured to facilitate passage of said fluid through said controlling member when said controlling member is in said opened configuration, said passage of said fluid within said second aperture is configured to preserve said controlling member in said opened configuration while said fluid passes through said controlling member; and any combination thereof. 21. The method for delivering a substance to a nasal cavity of a subject according to claim 17, further comprising at least one step selected from a group consisting of (a) reconfiguring said valve from said inactive configuration to said active configuration when said pressure gradient is above a predetermined threshold; (b) providing said valve with a spring which is at least partially tensed in said inactive configuration, and at least partially released in said active configuration; (c) providing said valve with a spring which is at least partially released in said inactive configuration, and at least partially tensed in said active configuration; (d) closing the soft palate of said subject as a result of said step (f) of drinking said fluid, and thereby substantially isolating the nasal passageways of the nose of said subject from the pulmonary system; (e) compressing said substance within said container via a piston; (f) providing said trigger mechanism with a pulsation mechanism configured to reconfigure said valve from said inactive configuration to said active configuration and vice versa in sequence of pulses, each of which is characterized by a predetermined length of pulse, said valve configured to release said predetermined amount of said substance according to said sequence of pulses; and any combination thereof. 22. The method for delivering a substance to a nasal cavity of a subject according to claim 17, wherein at least one of the following is being held true (a) said tubule is at least partially a straw; (b) said fluid is selected from a group consisting of: water, juice, a fluid medication, a cold fluid, a warm fluid, and any combination thereof. 23. The method for delivering a substance to a nasal cavity of a subject according to claim 17, further comprising step of synchronizing operation of said trigger mechanism with said drinking of said fluid by said subject. 24. The method for delivering a substance to a nasal cavity of a subject according to claim 17, further comprising a step of providing said device with a cap configured to cover at least a portion of the components of said device for sterilization purposes; wherein said cap comprises an opening. 25. The method for delivering a substance to a nasal cavity of a subject according to claim 17, wherein said container is configured to be connected to an external container, said external container configured to fill said container with said substance; further comprising a step of filling said container by said external container with a predetermined dose of said substance. 26. The method for delivering a substance to a nasal cavity of a subject according to claim 17, further comprising a step of providing said container with indicating means configured to indicate the amount of said substance within said container; wherein said indicating means is a transparent window located on a side of said container. 27. The method for delivering a substance to a nasal cavity of a subject according to claim 17, additionally comprising a step of selecting said substance from a group consisting of a drug selected from a group consisting of: Anti-Angiogenesis agents, Antisense, anti-ulcer, butorphanol, Calcitonin and analogs, COX-II inhibitors, desmopressin and analogs, dihydroergotamine, Dopamine agonists and antagonists, Enkephalins and other opioid peptides, Growth hormone and analogs, growth hormone releasing hormone, Growth hormone antagonists, IgE suppressors, Insulin, insulinotropin and analogs, Ketamine, Kytril, Leutenizing hormone releasing hormone and analogs, lidocaine, metoclopramide, Midazolam, Narcotic analgesics, neuraminidase inhibitors, nicotine, Non-steroid anti-inflammatory agents, Oligosaccharides, ondansetron, Parathyroid hormone and analogs, Parathyroid hormone antagonists, Prostaglandin antagonists, Prostaglandins, Recombinant soluble receptors, scopolamine, Serotonin agonists and antagonists, Sildenafil, Terbutaline, vasopressin, a vaccine with or without carriers and/or adjuvant selected from the group consisting of: Prophylactics and therapeutic antigens, subunit protein, peptide and polysaccharide, polysaccharide conjugates, toxoids, genetic based vaccines, live attenuated, reassortant, inactivated, whole cells, viral and bacterial vectors for the treatment of arthritis, Lactobacillus species: Lactobacillus acetotolerans, Lactobacillus acidifarinae, Lactobacillus acidipiscis, Lactobacillus acidophilus (Doderlein bacillus), Lactobacillus agilis, Lactobacillus algidus, Lactobacillus alimentarius, Lactobacillus amylolyticus, Lactobacillus amylophilus, Lactobacillus amylotrophicus, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus antri, Lactobacillus apodemi, Lactobacillus aviarius, Lactobacillus bifermentans, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus camelliae, Lactobacillus casei, Lactobacillus catenaformis, Lactobacillus ceti, Lactobacillus coleohominis, Lactobacillus collinoides, Lactobacillus composti, Lactobacillus concavus, Lactobacillus coryniformis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus diolivorans, Lactobacillus equi, Lactobacillus equigenerosi, Lactobacillus farraginis, Lactobacillus farciminis, Lactobacillus fermentum, Lactobacillus fornicalis, Lactobacillus fructivorans, Lactobacillus frumenti, Lactobacillus fuchuensis, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus gastricus, Lactobacillus ghanensis, Lactobacillus graminis, Lactobacillus hammesii, Lactobacillus hamsteri, Lactobacillus harbinensis, Lactobacillus hayakitensis, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus homohiochii, Lactobacillus iners, Lactobacillus ingluviei, Lactobacillus intestinalis, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kalixensis, Lactobacillus kefiranofaciens, Lactobacillus kefiri, Lactobacillus kimchii, Lactobacillus kitasatonis, Lactobacillus kunkeei, Lactobacillus leichmannii, Lactobacillus lindneri, Lactobacillus malefermentans, Lactobacillus mali, Lactobacillus manihotivorans, Lactobacillus mindensis, Lactobacillus mucosae, Lactobacillus murinus, Lactobacillus nagelii, Lactobacillus namurensis, Lactobacillus nantensis, Lactobacillus oligofermentans, Lactobacillus oris, Lactobacillus panis, Lactobacillus pantheris, Lactobacillus parabrevis, Lactobacillus parabuchneri, Lactobacillus paracollinoides, Lactobacillus parafarraginis, Lactobacillus parakefiri, Lactobacillus paralimentarius, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus perolens, Lactobacillus plantarum, Lactobacillus pontis, Lactobacillus psittaci, Lactobacillus rennini, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus rimae, Lactobacillus rogosae, Lactobacillus rossiae, Lactobacillus ruminis, Lactobacillus saerimneri, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus sanfranciscensis, Lactobacillus satsumensis, Lactobacillus secaliphilus, Lactobacillus sharpeae, Lactobacillus siliginis, Lactobacillus spicheri, Lactobacillus suebicus, Lactobacillus thailandensis, Lactobacillus ultunensis, Lactobacillus vaccinostercus, Lactobacillus vaginalis, Lactobacillus versmoldensis, Lactobacillus vini, Lactobacillus vitulinus, Lactobacillus zeae, Lactobacillus zymae, Probiotics selected from a group consisting of Lactic acid bacteria (LAB) and bifidobacteria, or any combination thereof; said substance is used for the treatment of at least one selected from a group consisting of cholera, moraxella catarrhali, cocaine addiction, Hib, meningococcus, measles, mumps, rubella, varicella, yellow fever, Respiratory syncytial virus, pneumococcus, streptococcus, typhoid, influenza, hepatitis, including hepatitis A, B, C and F, polio, HIV, parainfluenza, rotavirus, CMV, chlamydia, non-typeable haemophilus, moraxella catarrhalis, human papilloma virus, tuberculosis including BCG, gonorrhoea, asthma, atheroschlerosis, malaria, otitis media, E-coli, Alzheimers, H. Pylori, salmonella, diabetes, cancer and herpes simplex, Staphylococcus aureus, Streptococcus, a therapeutic substance selected from a group consisting of: Agents for the common cold, Anti-addiction, anti-infectives, analgesics, anesthetics, anorexics, antiarthritics, anti-allergy agents, antiasthmatic agents, anticonvulsants, anti-depressants, antidiabetic agents, anti-depressants, anti-diuretics, anti-emetics, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations, antinauseants, antineoplastics, anti-obesity, antiosteoporeteic, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antagonists, bone stimulating agents, central nervous system stimulants, hormones, hypnotics, immunosuppressives, prostaglandins, proteins, peptides, polypeptides and other macromolecules, psychostimulants, rhinitis treatment, sedatives, sexual hypofunction, tranquilizers and vitamins including B12, probiotics, natural oils, natural ingredients, peptide or protein therapeutic agent such as cytokines, hormones, clotting factors, vaccines, monoclonal antibody, natural oils; Mint oils, Peppermint oil, Spearmint oil, Menthol, Olive oil, Eucalyptus oil, Amino acids, fatty acids, or any combination thereof. 28. The method for delivering a substance to a nasal cavity of a subject according to claim 17, wherein at least one of the following is being held true (a) said substance is used for the treatment of at least one selected from a group consisting of cholera, moraxella catarrhali, cocaine addiction, HIB, meningococcus, measles, mumps, rubella, varicella, yellow fever, Respiratory syncytial virus, pneumococcus, streptococcus, typhoid, influenza, hepatitis, including hepatitis A, B, C and F, polio, HIV, parainfluenza, rotavirus, CMV, chlamydia, non-typeable haemophilus, moraxella catarrhalis, human papilloma virus, tuberculosis including BCG, gonorrhoea, asthma, atheroschlerosis, malaria, otitis media, E-coli, H. Pylori, salmonella, diabetes, cancer and herpes simplex, Staphylococcus aureus, Streptococcus, CNS disorder, brain disorders such as: brain cancer, acute brain injury, spinal cord injury, Alzheimer's disease, Neurogenesis, Parkinson's disease, depression, Epilepsy, schizophrenia by the delivery of substances such as: Neurotrophins, BDNF, GDNF, anti EGF receptor AB, Enzymes as Lysosomal enzyme, Neuregulin or any combination thereof; (b) said substance may be delivered to said nasal cavity in a form selected from the group consisting of: a powder; a granule; a cachet; a capsule; a tablet; a paste; a cream; a gel; an ointment; a salve; a foam; a paste; a lotion; a cream; an oil suspension; a spray; a suspension; a solution; an emulsion; a patch; a stick; a spray, preferably a nasal spray, or a buccal spray; a mouth wash; an aerosol, from a Venturi effect; a drink; and any combination thereof.

Details for Patent 9,227,031

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2039-03-29
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-03-29